Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00VZZ
|
|||
| Former ID |
DNC012876
|
|||
| Drug Name |
Allopregnanolone
|
|||
| Synonyms |
516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Approved | [1] | |
| Postpartum depression [ICD-11: 6E20.0] | Approved | [1], [2] | ||
| Status epilepticus seizure [ICD-11: 8A66.1Y] | Phase 3 | [3], [4] | ||
| Essential tremor or related tremors [ICD-11: 8A04.1; ICD-10: G25.0] | Phase 2 | [4] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H34O2
|
|||
| Canonical SMILES |
CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)O)C)C
|
|||
| InChI |
1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
|
|||
| InChIKey |
AURFZBICLPNKBZ-SYBPFIFISA-N
|
|||
| CAS Number |
CAS 516-54-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
586301, 7978606, 10225577, 12208574, 14826064, 14923739, 24278659, 44423581, 47513077, 47586678, 49836635, 50019556, 57335345, 74846894, 85300819, 85788331, 87550959, 92298224, 93167087, 95613568, 103489280, 104074460, 104408358, 124583834, 124892416, 126524062, 126688946, 127461832, 134350081, 135049778, 144205595, 144238831, 162089001, 178100930, 179236194, 184545674, 198958618, 198993875, 223672111, 224946688, 226892359, 241204043
|
|||
| ChEBI ID |
CHEBI:50169
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA(A) receptor alpha-1 (GABRA1) | Target Info | Inhibitor | [5] |
| GABA(A) receptor beta-2 (GABRB2) | Target Info | Inhibitor | [5] | |
| GABA(A) receptor delta (GABRD) | Target Info | Inhibitor | [1] | |
| GABA(A) receptor gamma-2 (GABRG2) | Target Info | Inhibitor | [5] | |
| GABA(A) receptor gamma-3 (GABRG3) | Target Info | Modulator | [2], [4] | |
| Gamma-aminobutyric acid receptor (GAR) | Target Info | Inhibitor | [6] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Retrograde endocannabinoid signaling | ||||
| Serotonergic synapse | ||||
| GABAergic synapse | ||||
| Morphine addiction | ||||
| Nicotine addiction | ||||
| Reactome | Ligand-gated ion channel transport | |||
| GABA A receptor activation | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| Iron uptake and transport | ||||
| SIDS Susceptibility Pathways | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. | |||
| REF 6 | Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.